Day

February 9, 2023
PRESS RELEASE REGULATED INFORMATION 09 February 2023, 07:00 CEST   alfapump® – successful primary endpoint read-out of North American pivotal POSEIDON study / PMA[1] filing planned for H2 2023 DSR® (Direct Sodium Removal) – clinical evidence of disease-modifying heart failure drug therapy, on track to start US Phase 1/2a MOJAVE study in Q2 2023 Total...
Read More
PRESS RELEASE Regulated information 09 February 2023, 07:00 am CEST   Ghent, Belgium – 09 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received transparency notifications from the shareholders listed...
Read More

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES